Georgetown University Medical Center

COVID-19 Symptom Tracker Ensures Privacy During Isolation

Newswise — WASHINGTON (August 13, 2020)— An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person’s confidentiality while being able to actively monitor their symptoms. The tool is not proprietary and can be used by entities that are not able to develop their own tracking systems.

Identifying and monitoring people infected with COVID-19, or exposed to people with infection, is critical to preventing widespread transmission of the disease. Details of the COVID19 Symptom Tracker and a pilot study were published August 13, 2020, in the Journal of Medical Internet Research (JMIR).

“One of the major impediments to tracking people with, or at risk of, COVID-19 has been an assurance of privacy and confidentiality,” says infectious disease expert Seble G. Kassaye, MD, MS, lead author and associate professor of medicine at Georgetown University Medical Center. “Our online system provides a method for efficient, active monitoring of large numbers of individuals under quarantine or home isolation, while maintaining privacy.”

The Georgetown internet tool assigns a unique identifier as people enter their symptoms and other relevant demographic data. One function in the system allows institutions to generate reports about items on which people can act, such as symptoms that might require medical attention. Additionally, people using the system are provided with information and links to Centers for Disease Control and Prevention COVID-19 recommendations and instructions for how people with symptoms should seek care.

Development of the system was rapid -- it took five days to design. The joint project included Georgetown University’s J.C. Smart, PhD, chief scientist of AvesTerra, a knowledge management environment that supports data integration and synthesis to identify actionable events and maintain privacy, and Georgetown’s vice president for research and chief technology officer, Spiros Dimolitsas, PhD.

“We knew that time was of the essence and the challenges of traditional contact tracing became very clear to us based on one of our first patients who had over 500 exposures,” says Kassaye. “This was what motivated us to work on this, essentially day and night.”

The tool launched on March 20, followed by initial testing of the system with the voluntary participation of 48 Georgetown University School of Medicine students or their social contacts. Participants were asked to enter data twice daily for three days between March 31 and April 5, 2020.

“The lack of identifying data being collected in the system should reassure individual users and alleviate personal inhibitions that appear to be the Achille’s heel of other digital contact tracing apps that require identifying information,” says Kassaye. She also noted that this system could be used by health-related organizations during the re-opening of business to provide reassurance to their users that the enterprise is actively, rather than passively, monitoring its staff.

Feedback from healthcare groups using the platform led to the release of a Spanish language version. As the data currently needs to be entered through the website, development of an app for cellphone use could greatly enhance the usability of the tool, said the investigators. For places where internet access is problematic, the researchers are also pursuing development of a voice activated version.

The tracker can be view at


In addition to Kassaye, Amanda B. Spence of Georgetown University Medical Center contributed to this work. Other authors include Edwin Lau and John Cederholm, LEDR Technologies Inc.; and David M. Bridgeland, Hanging Steel Productions LLC.

This work was partially supported by a National Institutes of Health grant UL1TR001409. The authors report no conflicts of interest.

Reference: Kassaye SG et al. Privacy-assured, Freely Available COVID-19 Symptom Tracker for Public Safety During Reopening: Feasibility and Functionality with Rapid Deployment. Journal of Medical Internet Research, Volume 6, No. 20, (2020): Jul-Sep 

About Georgetown University Medical Center
Georgetown University Medical Center (GUMC) is an internationally recognized academic health and science center with a four-part mission of research, teaching, service and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization, which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.  Connect with GUMC on Facebook (, Twitter (@gumedcenter).



Filters close

Showing results

110 of 3327
Newswise: How to Keep Children Safe from COVID-19 this Fall
Released: 18-Sep-2020 4:15 PM EDT
How to Keep Children Safe from COVID-19 this Fall
Rush University Medical Center

With the new school year started and autumn approaching, Colleen Nash, MD, MPH, Rush University Medical Center, pediatric infectious disease specialist, answers questions parents may have about keeping children safe from COVID, social distancing in the classroom and celebrating Halloween.

Released: 18-Sep-2020 4:05 PM EDT
Claims circulating on social media stating that the common cold or flu can be mistaken for COVID-19 are misleading

The claims rely on the faulty assumption that there is no method to distinguish COVID-19 from the common cold and the flu.

Released: 18-Sep-2020 3:35 PM EDT
After developing CRISPR test, UConn researchers validate clinical feasibility for COVID-19 testing
University of Connecticut

In March, researchers in the Department of Biomedical Engineering-- a shared department in the schools of Dental Medicine, Medicine, and Engineering--began to develop a new, low-cost, CRISPR-based diagnostic platform to detect infectious diseases, including HIV virus, the novel coronavirus (SARS-CoV-2).

Newswise:Video Embedded blowin-in-the-wind
Released: 18-Sep-2020 3:10 PM EDT
Blowin' in the wind
University of Utah

University of Utah chemical engineers have conducted an air flow study of the venue that the Utah Symphony performs in to determine the best ways to mitigate the spread of COVID-19 through the emissions of wind instrument players.

Newswise: holman1_toned-1-768x512.jpg
Released: 18-Sep-2020 2:50 PM EDT
Study links rising stress, depression in U.S. to pandemic-related losses, media consumption
University of California, Irvine

Irvine, Calif., Sept. 18, 2020 – Experiencing multiple stressors triggered by the COVID-19 pandemic – such as unemployment – and COVID-19-related media consumption are directly linked to rising acute stress and depressive symptoms across the U.S., according to a groundbreaking University of California, Irvine study. The report appears in Science Advances, published by the American Association for the Advancement of Science.

Newswise: 243389_web.jpg
Released: 18-Sep-2020 10:55 AM EDT
Potential new drug to mitigate SARS-CoV-2 infection consequences
University of Malaga

Scientists from the Department of Cell Biology of the University of Malaga (UMA) and the Andalusian Centre for Nanomedicine and Biotechnology (BIONAND) have made progress in finding new rapid implementation therapies to combat the COVID-19 pandemic, identifying a new drug that could prevent or mitigate the consequences derived from SARS-CoV-2 infection.

Newswise: 243400_web.jpg
Released: 18-Sep-2020 10:40 AM EDT
Most homemade masks are doing a great job, even when we sneeze, study finds
University of Illinois at Urbana-Champaign

Studies indicate that homemade masks help combat the spread of viruses like COVID-19 when combined with frequent hand-washing and physical distancing.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Sep-2020 8:00 AM EDT Released to reporters: 18-Sep-2020 10:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Sep-2020 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Sep-2020 8:30 AM EDT
Immunotherapy Drug Development Pipeline Continues Significant Growth in 2020 Despite Global Pandemic Impact
Cancer Research Institute

Despite the impact of the COVID-19 pandemic across the globe, there has been a resurgence of interest in immuno-oncology (I-O) preclinical and clinical development, bringing hope to cancer patients and physicians who treat them.

Showing results

110 of 3327